Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease
Study Details
Study Description
Brief Summary
This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease. This study also will examine the safety and tolerability of the drug. This study is evaluating 3 different dose levels of ST101 and placebo. Patients will have a 1 in 4 chance of getting placebo.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
Alzheimer's disease (AD) is a progressive and fatal neurological illness. It produces changes in the brain that include loss of cells and accumulation of abnormal protein deposits. Initial symptoms are cognitive, with deficiencies in short-term memory the most common symptom. As the disease progresses so does the severity of cognitive deficiency. Loss of speech and immobility occur in the terminal stages There is no cure for AD and no marketed treatment that modifies the underlying disease process. Available therapies improve some symptoms of AD by increasing brain concentrations of molecules involved in cognition. ST101 differs from marketed therapies in that it has demonstrated two actions in animal research testing. It improves cognition and it also reduces the accumulation of abnormal protein deposits in the brain. These two properties suggest that ST101 may be a promising agent for the treatment of AD. This study is designed as a preliminary dose exploration/proof-of-concept investigation of the ability of ST101 to improve cognition during 12 weeks of administration.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: 1 30 mg ST101 |
Drug: ST101
30 mg; administered once/day
|
Experimental: 2 90 mg ST101 |
Drug: ST101
90 mg; administered once/day
|
Experimental: 3 180 mg ST101 |
Drug: ST101
180 mg; administered once/day
|
Placebo Comparator: 4 Placebo |
Drug: Placebo
placebo to match ST101 tablets
|
Outcome Measures
Primary Outcome Measures
- Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-cog) [Baseline, 4 weeks, 8 weeks,12 weeks]
Secondary Outcome Measures
- Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) [Baseline, 4 weeks, 8 weeks, 12 weeks]
- Neuropsychiatric Inventory (NPI) [Baseline, 4 weeks, 8 weeks, 12 weeks]
- Alzheimer's Disease Cooperative Study- Clinical Global Impression (ADCS-CGI) [Baseline (severity); 4 weeks, 8 weeks, 12 weeks (change)]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnostic evidence of mild to moderate Alzheimer's disease.
-
CT or MRI results within the past 12 months that rule out dementia due to non-Alzheimer's etiology.
-
A reliable and capable caregiver.
Exclusion Criteria:
-
Subjects who reside in a skilled nursing facility.
-
Subjects with B12 or folate deficiency.
-
Subjects with chronic hepatic disease.
-
Subjects with a recent history of hematologic/oncologic disorders.
-
Subjects who have experienced a myocardial infarction with the past year.
-
Dementia caused or complicated by other organic disease
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Costa Mesa | California | United States | ||
2 | Redlands | California | United States | ||
3 | San Diego | California | United States | ||
4 | Walnut Creek | California | United States | ||
5 | Deerfield Beach | Florida | United States | ||
6 | Delray Beach | Florida | United States | ||
7 | Orlando | Florida | United States | ||
8 | West Palm Beach | Florida | United States | ||
9 | Indianapolis | Indiana | United States | ||
10 | Shreveport | Louisiana | United States | ||
11 | Durham | North Carolina | United States | ||
12 | Toledo | Ohio | United States | ||
13 | Jenkinton | Pennsylvania | United States | ||
14 | Wichita Falls | Texas | United States | ||
15 | Bennington | Vermont | United States | ||
16 | Peterborough | Ontario | Canada | ||
17 | Toronto | Ontario | Canada | ||
18 | Montreal | Quebec | Canada |
Sponsors and Collaborators
- Sonexa Therapeutics, Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ST101-A001-201